S
Sharon Yunger
Researcher at Sheba Medical Center
Publications - 6
Citations - 1273
Sharon Yunger is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Immunotherapy & Antigen. The author has an hindex of 4, co-authored 4 publications receiving 915 citations.
Papers
More filters
Journal ArticleDOI
m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation
Shay Geula,Sharon Moshitch-Moshkovitz,Dan Dominissini,Abed AlFatah Mansour,Nitzan Kol,Mali Salmon-Divon,Vera Hershkovitz,Eyal Peer,Nofar Mor,Yair S. Manor,Moshe Shay Ben-Haim,Eran Eyal,Sharon Yunger,Yishay Pinto,Diego Jaitin,Sergey Viukov,Yoach Rais,Vladislav Krupalnik,Elad Chomsky,Mirie Zerbib,Itay Maza,Yoav Rechavi,Rada Massarwa,Suhair Hanna,Suhair Hanna,Ido Amit,Erez Y. Levanon,Ninette Amariglio,Ninette Amariglio,Noam Stern-Ginossar,Noa Novershtern,Gideon Rechavi,Jacob H. Hanna +32 more
TL;DR: It is shown that N6-methyladenosine (m6A), a messenger RNA (mRNA) modification present on transcripts of pluripotency factors, drives this transition from the pluripotent to the differentiated state.
Journal ArticleDOI
Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.
Sivan Seliktar-Ofir,Efrat Merhavi-Shoham,Orit Itzhaki,Sharon Yunger,Gal Markel,Gal Markel,Jacob Schachter,Michal J. Besser,Michal J. Besser +8 more
TL;DR: CD137-selected TIL demonstrated significantly increased antitumor reactivity and were enriched for T cells recognizing neoantigens as well as shared tumor antigens, enabling the enrichment of tumor-reactive T cells without the necessity of knowing the epitope specificity or the antigen type.
Journal ArticleDOI
Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy.
Sharon Yunger,Assaf Bar El,Li at Zeltzer,Eddie Fridman,Eddie Fridman,Gil Raviv,Menachem Laufer,Jacob Schachter,Gal Markel,Gal Markel,Orit Itzhaki,Michal J. Besser,Michal J. Besser +12 more
TL;DR: It is demonstrated that functional and anti-tumor reactive TIL can be obtained, despite the immunosuppressive microenvironment of the cancer, thus this study supports the development of TIL therapy for prostate cancer patients.
Journal ArticleDOI
Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides
TL;DR: In this article, the peptide-MHC binding affinity and the number of peptides reaching the ER were correlated with the response of T-cells to neo-antigens. And the classifier properties further highlighted the contribution of the peptides reached the ER and the mutation type to CD8-+-T cell responses.
Posted ContentDOI
Modulating the proliferative and cytotoxic properties of human TIL by a synthetic immune niche of immobilized CCL21 and ICAM1
TL;DR: The results demonstrate the potential capacity of the CCL21+ICAM1 SIN to reinforce TIL-based immunotherapy, following activation with immobilized anti-CD3/CD28 stimulation, or commercial activation beads.